Application of USP21-MOF regulation axis in preparation of drugs for targeted therapy of esophageal squamous cell carcinoma
The invention relates to application of a USP21-MOF regulation axis in preparation of drugs for targeted therapy of esophageal squamous cell carcinoma. And the USP21-MOF regulation and control axis comprises a USP21 gene and an MOF gene. The mRNA nucleotide sequence of the USP21 gene is as shown in...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | chi ; eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The invention relates to application of a USP21-MOF regulation axis in preparation of drugs for targeted therapy of esophageal squamous cell carcinoma. And the USP21-MOF regulation and control axis comprises a USP21 gene and an MOF gene. The mRNA nucleotide sequence of the USP21 gene is as shown in SEQ ID NO. 1, and the mRNA nucleotide sequence of the MOF gene is as shown in SEQ ID NO. 2. According to the invention, it is found for the first time that proliferation, migration and invasion of esophageal squamous cell carcinoma cells can be effectively inhibited through interference inhibition of a USP21-MOF regulatory axis, and si-USP21, si-MOF and si-UM which specifically knock down expression levels of mRNA of USP21 and MOF are designed. The invention also finds that the inhibition effect of knocking down the mRNA expression level of USP21 and MOF at the same time on a USP21-MOF regulation axis is optimal, the effect of inhibiting proliferation and metastasis of esophageal squamous cell carcinoma is optimal, |
---|